The stock's fall snapped a two-day winning streak.

Corporate borrowing surged to a record in 2024, up over a third from a year earlier as companies like AbbVie and Cisco looked ...

Non-transplant salvage therapy for low-risk relapsed/refractory pediatric classical Hodgkin lymphoma (cHL) had high rates of ...

PRINCETON, N.J., January 03, 2025 -- ( BUSINESS WIRE )-- Bristol Myers Squibb (NYSE: BMY) today announced that the company will present at J.P. Morgan’s 43 rd Annual Healthcare Conference on Monday, ...

Several large drugmakers, including Pfizer, Bristol Myers Squibb and Sanofi, increased the list prices of their drugs this month.

Drugmakers plan to raise US prices on at least 250 branded medications including Pfizer COVID-19 treatment Paxlovid, Bristol ...

The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use for most previously approved adult, solid tumor Opdivo (nivolumab) ...

Neumora Therapeutics' lead candidate, navacaprant, failed to meet primary and secondary endpoints in its Phase 3 KOASTAL-1 ...

Viper Partners, a premier leader in healthcare investment banking, announces its continued commitment to the growth and advancement of vascular surgery practices nationwide. By facilitating strategic ...

Researchers have applied AI to every step of the drug development process. But this might not be enough to design safe and effective drugs.

Pfizer ( PFE +0.45% ) led the latest round of hikes, raising prices on over 60 drugs — more than any other company. This includes a 3% increase for the company’s COVID-19 treatment, Paxlovid, and ...